Target Validation Information | |||||
---|---|---|---|---|---|
TTD ID | T77400 | ||||
Target Name | Phosphodiesterase 2A (PDE2A) | ||||
Type of Target |
Clinical trial |
||||
Drug Potency against Target | (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol | Drug Info | Ki = 1000 nM | [2] | |
2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one | Drug Info | IC50 = 6000 nM | [1] | ||
BAY-60-7550 | Drug Info | IC50 = 4.7 nM | [2] | ||
Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine | Drug Info | IC50 = 19000 nM | [4] | ||
Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine | Drug Info | IC50 = 17000 nM | [4] | ||
isobutylmethylxanthine | Drug Info | IC50 = 12000 nM | [3] | ||
References | |||||
REF 1 | PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2847-51. | ||||
REF 2 | The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62. | ||||
REF 3 | A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. | ||||
REF 4 | Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.